- ANGLE has announced new results from its key opinion leader, Barts Cancer Institute (BCI), investigating the clinical use of the Parsortix system in prostate cancer patients.

Prostate cancer is the second most common cancer in men and the fourth most common overall. More than 1.1 million cases of prostate cancer were recorded in 2012, accounting for around 8 per cent of all new cancer cases and 15 per cent in men (Source: World Cancer Research Fund International).

BCI, part of Queen Mary University of London's School of Medicine & Dentistry, is home to world-class clinical, translational and basic scientific research and is one of the top five cancer research centres in the UK. BCI is publishing the results of the most recent phase of its work at a symposium hosted by the British Association for Cancer Research and Cancer Research UK on "Evolution and Intratumoural Heterogeneity" being held today at the Royal Society of Medicine, London. A copy of the poster publication is available on the ANGLE website:

Story provided by